CinCor Pharma’s $143 Million Series B Financing

Wilson Sonsini Goodrich & Rosati represented General Atlantic on the transaction.

CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing was led by General Atlantic, a leading global growth equity firm, with participation from new investors Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, and Sixty Degree Capital, alongside existing investors Sofinnova Investments, Sofinnova Partners, 5AM Ventures and CinRx.

The proceeds from the round will support the continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate in development for the treatment of hypertension, primary aldosteronism, and chronic kidney disease. The new funding will enable completion of the ongoing brigHTN Phase 2 clinical trial in patients with resistant hypertension as well as the ongoing Phase 2 Spark trial in hypertensive individuals with primary aldosteronism; in addition, it will support initiation of two new trials, a Phase 2 clinical trial (HALO) in patients with uncontrolled hypertension and a study of CIN-107’s impact on blood pressure and kidney function in patients with chronic kidney disease (CKD).

The Wilson Sonsini team that advised General Atlantic on the transaction include John Brust (Picture), Lowell Segal, Mike Hostetler, Julia Minitti, Luis Perla, and Amanda Creedon.

Involved fees earner: John Brust – Wilson Sonsini Goodrich & Rosati; Amanda Creedon – Wilson Sonsini Goodrich & Rosati; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Julia Minitti – Wilson Sonsini Goodrich & Rosati; Luis Perla – Wilson Sonsini Goodrich & Rosati; Lowell Segal – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: General Atlantic;

Author: Martina Bellini